albicans biofilms was tested against highly developed biofilms of intermediate and maturation phase. In contrast to previous investigation by Chandra et al. [11] and Cocuaud et al. [16], we did not analyse resistance of Candida biofilm in the early phase of development because of low biofilm formation within less than 24 h (OD ≤ 0.5). We found higher activity of CAS and amphotericin B in reduction of metabolic activity of biofilms grown for 24 h and 72 h compared to biofilms grown for 48 h, whereas POS showed similar activity in all development phases

Adriamycin clinical trial tested. Caspofungin and amphotericin B, both agents with the action site at the fungal cell wall, reduced significantly the OD of biofilms grown for 24 h and 72 h, but Selleckchem Crizotinib only little effect was observed in 48-h old biofilms. Caspofungin was the most effective antifungal agent in biofilm reduction regardless of the tested development phase. The echinocandin achieved a ≥ 50%

reduction of 24-h and 72-h old biofilm even at low concentration of 1 × MIC. At higher concentrations, CAS showed diminished reduction in C. albicans biofilm, particularly for biofilm grown for 48 h. The phenomena of lower reduction in higher concentrations termed as paradoxical effect, characteristic for CAS, was already described for both, planktonic cells and biofilm.26,27 In the in vitro study of Melo et al. [27], paradoxical effect of CAS has been seen in 40% of planktonic cells and 80% of Candida biofilm. However, the clinical significance of paradoxical effect is still unclear. Previously, CAS has also been demonstrated as the best antifungal agent in biofilm reduction with decrease in C. albicans biofilm of 50% already at concentration of MIC for planktonic cells.28–30 However, no difference in susceptibility between 24-h29 and 48-h old biofilm30 against CAS has been detected. In contrast to these studies, Cocuaud et al. [16] showed no significant activity of CAS at concentration of 1 × MIC to reduce ≥50% XTT activity of C. albicans in all three development phases. Although when used in therapeutic concentrations (2 mg/l), CAS caused a significant reduction in biofilm metabolic activity.16,23 Amphotericin B, classic

polyene antifungal, reduced the biofilm OD by ≥50% in 24-h and 72-h old biofilms; however, at the higher concentrations. In contrast to CAS, amphotericin B showed concentration-dependent activity on C. albicans biofilms. Verteporfin mouse However, we could not observe a correlation between age of Candida biofilm and resistance to amphotericin B, as described by Chandra et al. using silicone elastomere disk model.11 Although reducing the biofilm OD only significantly by 20–35%, POS showed similar activity against all tested development phases. Our results confirm the finding of Katragkou et al., the disability of the new azoles, such as voriconazole and POS to reduce the C. albicans biofilm OD of ≥50%.30 In this study, Katragkou et al. demonstrated a maximum decrease in the biofilm OD by 40% against two C.